Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blaise

Showing results (201-210 of 284) with videos related to

Pageof 29
Sort By:
Bone Marrow Transplantation|March 12, 2014
Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)X Cahu, P Chevallier, A Clavert, et al.
Annals of Hematology|February 24, 2020
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcomeB Bouchacourt, M A Hospital, C Zemmour, et al.
Blood|September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's diseaseM André, M Henry-Amar, D Blaise, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registryA Sadowska-Klasa, J M Zaucha, M Labopin, et al.
Bone Marrow Transplantation|July 1, 2014
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMTM A Kharfan-Dabaja, M Labopin, A Bazarbachi, et al.
Bone Marrow Transplantation|September 15, 2015
Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell TherapyS P Chantepie, M Michallet, D Blaise, et al.
Bone Marrow Transplantation|April 15, 2003
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationA J Peniket, M C Ruiz de Elvira, G Taghipour, et al.
Annals of Internal Medicine|April 15, 1997
Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trialO Hartmann, A G Le Corroller, D Blaise, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 24, 2013
Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patientsG Venton, R Crocchiolo, S Fürst, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Pageof 29

Showing results (201-210 of 284) with videos related to

Sort By:
Pageof 29
Bone Marrow Transplantation|March 12, 2014
Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)X Cahu, P Chevallier, A Clavert, et al.
Annals of Hematology|February 24, 2020
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcomeB Bouchacourt, M A Hospital, C Zemmour, et al.
Blood|September 10, 1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's diseaseM André, M Henry-Amar, D Blaise, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registryA Sadowska-Klasa, J M Zaucha, M Labopin, et al.
Bone Marrow Transplantation|July 1, 2014
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMTM A Kharfan-Dabaja, M Labopin, A Bazarbachi, et al.
Bone Marrow Transplantation|September 15, 2015
Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell TherapyS P Chantepie, M Michallet, D Blaise, et al.
Bone Marrow Transplantation|April 15, 2003
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationA J Peniket, M C Ruiz de Elvira, G Taghipour, et al.
Annals of Internal Medicine|April 15, 1997
Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trialO Hartmann, A G Le Corroller, D Blaise, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 24, 2013
Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patientsG Venton, R Crocchiolo, S Fürst, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Pageof 29